Although the extent of the involvement of the amylin pathway modulation in migraine in unknown, and other mechanisms may play a role, this initial evidence may constitute a mechanistic substrate for trying CGRP mAb blocking the ligand in patients who fail to respond to the CGRP mAb blocking the receptor. The gene discussed is CALCA; the disease is migraine disorder.